ClinicalTrials.gg
RecruitingNCT06785636P300Updated Aug 20, 2026

A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

A Phase 1/2 interventional study of Pocenbrodib and Pocenbrodib and Darolutamide in mCRPC (Metastatic Castration-resistant Prostate Cancer) and Prostate Cancer, sponsored by Pathos AI, Inc.. Recruiting at 19 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Pathos AI, Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies testing darolutamide in Prostatic Neoplasms — 29 open to participants now, 40 under way, 10 of them phase 3. darolutamide · Prostatic Neoplasms.

Planned enrollment
25th of 59
120 · median 80
Started
2025
with 3 others
Phase 1/2
3 of 59
1 open now
Primary completion
2028-06
later than 28 of 39 live
Registered
49th of 59
by date

Among the 59 studies testing darolutamide in Prostatic Neoplasms, this one is the 25th largest by planned enrollment, is one of 4 that started in 2025, is one of 3 in phase 1/2, reaches primary completion later than 28 of the 39 other live ones, and was the 49th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

29 of the 59 studies testing darolutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About darolutamide

darolutamide: first FDA approval 2019 (NUBEQA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing darolutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)

Read the detailed description

This is a Phase 1b/2a multicenter, open-label study to confirm the safety, pharmacokinetics (PK), preliminary antitumor activity, and pharmacodynamics (PD) of pocenbrodib for the treatment of participants with mCRPC who have progressed following prior therapy and have been treated with at least 1 potent anti-androgen therapy (enzalutamide, apalutamide, abiraterone acetate, or darolutamide).

Phase 1b is a dose escalation and optimization study of pocenbrodib monotherapy and in combination with darolutamide in order to determine the maximum tolerated dose (MTD) in participants (n=80) and to determine the recommended Phase 2 dose(s) (RP2D(s)).

Phase 1b consists of three arms: Arm 1 (50-250mg QD 5/2), Arm 2 (continuous monotherapy, 125mg-150mg BID), and Arm 3 (continuous combination of pocenbrodib 125-150mg BID + darolutamide 600mg BID), with DRC safety gates governing study progression between arms. Arm 3 is considered the safety run-in for the combination therapy.

Phase 2a is a dose expansion portion of the study to further evaluate the combination of pocenbrodib and darolutamide in participants with mCRPC who have progressed following lutetium-Lu-177-vipivotide-tetraxetan (PLUVICTO) and prior to initiation of taxane-based therapy and will consist of 2 cohorts:

Cohort 1: pocenbrodib RP2D high + darolutamide

Cohort 2: pocenbrodib RP2D low + darolutamide

Safety will be monitored by the DRC

03

Conditions studied

  • mCRPC (Metastatic Castration-resistant Prostate Cancer)
  • Prostate Cancer

Browse trials for

Keywords

  • mCRPC, metastatic castrate resistant prostate cancer, prostate cancer,
  • darolutamide
  • Pocenbrodib
  • p300-CBP Transcription Factors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

1b / 2a Inclusion Criteria:

  1. ≥18 years of age
  2. Histologic documentation of prostate adenocarcinoma
  3. disease, documented by imaging. Imaging performed within 56 days prior to Screening is acceptable

1b / 2a Exclusion Criteria:

  1. Current or prior evidence of any small cell or neuroendocrine histology on the most recent prostate .
  2. Any liver metastases confirmed by biopsy or evidence of lesions >1 cm consistent with liver metastases on imaging.
  3. Intervention with any chemotherapy, agent, or other anticancer drug, including enzalutamide, apalutamide, or darolutamide, 14 days prior to Cycle 1 Day 1 or 5 half-lives (whichever is shorter).
  4. Any other serious underlying medical, psychiatric, psychological, familial, or geographical condition, which in the judgment of the Investigator may interfere with study participation and compliance or place the participant at high risk from treatment-related complications.

2a only -key inclusion criteria:

  1. Must have received at least 2 cycles of PLUVICTO®
  2. 1 line of prior any ARPI therapy
  3. No prior chemotherapy for mCRPC
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Phase 1b Arm 1

    Pocenbrodib 50-250 mg QD (5 days on/2 days off)

    Drug: Pocenbrodib

  • Experimental
    Phase 1b Arm 2

    Pocenbrodib 125-150 mg BID monotherapy

    Drug: Pocenbrodib

  • Experimental
    Phase 1b Arm 3

    Pocenbrodib 125-150 mg BID + darolutamide 600 mg

    Drug: Pocenbrodib and Darolutamide

  • Experimental
    Phase 2a portion

    Cohort 1: pocenbrodib RP2D-high + darolutamide Cohort 2: pocenbrodib RP2D-low + darolutamide

    Drug: Pocenbrodib and Darolutamide

Interventions

  • DrugPocenbrodib

    Pocenbrodib is a selective oral inhibitor of CBP/p300 bromodomain interaction with acetylated lysines on histones.

  • DrugPocenbrodib and Darolutamide

    Drug page: Darolutamide

    Pocenbrodib in combination with darolutamide

06

What researchers measure

Primary outcomes

  1. Phase 1b: Confirm the safety and tolerability of pocenbrodib and in combination with darolutamide

    Occurrence and severity of Serious Adverse Events (SAEs) and clinically relevant Adverse Events (AEs), and clinically significant changes in safety laboratory values and electrocardiograms (ECGs)

    Time frame: 28 days

  2. Phase 1b: Identify the recommended Phase 2 doses of pocenbrodib and in combination with darolutamide

    Frequency and type of DLTs used to determine the maximum tolerated dose (MTD) and RP2Ds

    Time frame: 28 days

  3. Phase 2a: Assess the safety and tolerability of the RP2Ds of pocenbrodib in combination with darolutamide

    1. Occurrence and severity of SAEs, clinically relevant AEs, and clinically significant changes in safety laboratory values, physical examination (PE) findings, vital signs, and ECGs. 2. Safety and selection of pocenbrodib RP2D for combination with darolutamide for subsequent development

    Time frame: Through duration of treatment, estimated 6 months

  4. Phase 2a: Evaluate the efficacy of RP2Ds of pocenbrodib in combination with darolutamide

    Post-177Lu-PSMA-617 (Post-PLUVICTO®) pre-taxane mCRPC: Radiographic progression-free survival (rPFS), assessed as time from randomization to first occurrence of Radiographic progression-free survival (rPFS) according to; i) Response Evaluation Criteria in Solid Tumors (RECIST v1.1) and ii) Prostate Cancer Working Group 3 (PCWG3) criteria or death from any cause, whichever comes first.

    Time frame: Through duration of treatment, estimated 6 months.

Secondary outcomes

  1. Phase 1b: Plasma PK Cmax

    Plasma PK parameter for Cmax

    Time frame: At the end of Cycle 1, 2, 3, and 4 (each cycle is 28 days) or until end of treatment, whichever came first

  2. Phase 1b: Plasma PK Tmax

    Plasma PK parameter for Tmax,

    Time frame: At the end of Cycle 1, 2, 3, and 4 (each cycle is 28 days) or until end of treatment, whichever came first

  3. Phase 1b: Plasma PK AUC for pocenbrodib

    Plasma PK AUC parameter for pocenbrodib. Pocenbrodib parameters compared to monotherapy Arms 1/2.

    Time frame: At the end of Cycle 1, 2, 3, and 4 (each cycle is 28 days) or until end of treatment, whichever came first.

  4. Phase 1b: Model of cumulative exposure in relation to incidence of adverse events (AEs)

    Time frame: Through duration of treatment, estimated 6 months.

  5. Phase 1b: Model of cumulative exposure in relation to incidence of serious adverse events (SAEs)

    Time frame: Through duration of treatment, estimated 6 months.

  6. Phase 1b: Model of cumulative exposure in relation to incidence of adverse events of special interest (AESIs)

    Time frame: Through duration of treatment, estimated 6 months.

  7. Phase 2a: Characterize the PK of pocenbrodib in combination with darolutamide

    Characterize the PK of pocenbrodib in combination with darolutamide in participants with mCRPC after progressing after 177Lu-PSMA-617 (PLUVICTO®) treatment

    Time frame: At the end of Cycle 1, 2, 3, and 4 (each cycle is 28 days) or until end of treatment, whichever came first

  8. Phase 2a: Plasma PK Cmax pocenbrodib/darolutamide

    Plasma PK parameter for Cmax for pocenbrodib and darolutamide combined

    Time frame: At the end of Cycle 1, 2, 3, and 4 (each cycle is 28 days) or until end of treatment, whichever came first

  9. Phase 2a: Plasma PK Tmax pocenbrodib/darolutamide

    Plasma PK parameter for Tmax for pocenbrodib and darolutamide combined

    Time frame: At the end of Cycle 1, 2, 3, and 4 (each cycle is 28 days) or until end of treatment, whichever came first

  10. Phase 2a: Plasma PK AUC0-24 pocenbrodib/darolutamide

    Plasma PK parameter for AUC0-24 for pocenbrodib and darolutamide combined

    Time frame: At the end of Cycle 1, 2, 3, and 4 (each cycle is 28 days) or until end of treatment, whichever came first

  11. Phase 2a: rPFS (radiographic Progression Free Survival)

    Evaluate efficacy parameters based on RECIST v1.1 and PCWG3 criteria for rPFS (radiographic Progression Free Survival)

    Time frame: Through duration of treatment, estimated 6 months

  12. Phase 2a: Prostate Specific Antigen (PSA) 50% (PSA50) change from baseline.

    Evaluate efficacy parameters based on RECIST v1.1 and PCWG3 criteria for Prostate Specific Antigen (PSA) 50% (PSA50) change from baseline

    Time frame: Through duration of treatment, estimated 6 months

  13. Phase 2a: Prostate Specific Antigen PSA 90% (PSA90) change from baseline.

    Evaluate efficacy parameters based on RECIST v1.1 and PCWG3 criteria for Prostate Specific Antigen PSA 90% (PSA90) change from baseline

    Time frame: Through duration of treatment, estimated 6 months

07

Study locations

19 of 19 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Pathos AI, Inc. will determine once safety and preliminary efficacy is defined.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Jun 2028, 40 months after the start.

Of 96 industry-sponsored phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35. This study's planned 40 months is below that.

Counting every sponsor, half of 210 studies reached it within 61 months; a quarter within 30 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2024
First posted
Jan 21, 2025
StartActual
Feb 7, 2025
Primary completionEst.
Jun 30, 2028
CompletionEst.
Apr 30, 2029
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06785636
Lead sponsor
Pathos AI, Inc.
Collaborators
Duke University
Responsible party
Sponsor
First posted
Jan 21, 2025
Start date
Feb 7, 2025
Primary completion
Jun 30, 2028 (estimated)
Completion
Apr 30, 2029 (estimated)
Last update
Aug 20, 2026

Study contacts

Steve Kye, MD, MPH
Contact
clinicaltrials@pathos.com
708-232-3791

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Darolutamide

Start the discussion